CMV-TCR-T cells

CMV-TCR-T cells are a form of adoptive cell therapy in which patient or donor-derived T lymphocytes are genetically engineered to express a transgenic T cell receptor (TCR) that specifically recognizes cytomegalovirus (CMV) antigens presented by certain human leukocyte antigen (HLA) molecules. This approach enables the rapid production of large numbers of virus-targeted effector T cells capable of recognizing and lysing CMV-infected or tumor cells. The most common target is the immunodominant pp65 protein of CMV. Compared to conventional cytotoxic T lymphocyte (CTL) therapy, these engineered TCR-T cells can be manufactured more efficiently and may offer improved specificity and safety due to their reliance on physiological signaling pathways. Clinical studies have demonstrated that adoptive transfer of CMV-specific TCR-engineered T cells is feasible, safe, and effective as pre-emptive or salvage therapy for patients with refractory or reactivated CMV infection following hematopoietic stem cell transplantation (HSCT), particularly after haploidentical peripheral blood stem cell transplantation[1][2][4][5].

Other names

CMV-specific TCR-T cellscytomegalovirus-specific TCR-engineered T cellspp65-specific TCR-T cellspp-65-specific TCR-T cellspp 65-specific TCR-T cells